Agenus (AGEN) announced the appointment of Jose Iglesias as chief medical affairs officer, effective November 10. Iglesias will lead global medical affairs for botensilimab and balstilimab as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Acces Compassionnel program.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus Inc. Reports Q3 2025 Financial and Clinical Progress
- Promising Developments and Strategic Partnerships Justify Buy Rating for Agenus
- Agenus reports Q3 EPS $1.94, consensus $2.20
- AGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Agenus Inc. Advances Cancer Treatment with Promising Study Update